Étiquette : publi

Publications du CNR en 2015

Amarsy-Guerle, R., Mougari, F., Jacquier, H., Oliary, J., Benmansour, H., Riahi, J., Berçot, B., Raskine, L. and Cambau, E. (2015). High medical impact of implementing the new polymeric bead-based BacT/ALERT® FAPlus and FNPlus blood culture bottles in standard care. European Journal of Clinical Microbiology & Infectious Diseases 34, 1031–1037, http://doi.org/10.1007/s10096-015-2319-8.
Bernard, C., Veziris, N., Brossier, F., Sougakoff, W., Jarlier, V., Robert, J. and Aubry, A. (2015). Molecular Diagnosis of Fluoroquinolone Resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 59, 1519–1524, http://doi.org/10.1128/AAC.04058-14.
Brossier, F., Sola, C., Bernard, C., Jarlier, V., Veziris, N. and Sougakoff, W. (2015). Characterization of a Clone of Mycobacterium tuberculosis Clinical Isolates with Mutations in KatG (A110V), EthA (Q269STOP), and the inhA Promoter (−15C→T) Ed. Land, G. A. Journal of Clinical Microbiology 53, 3104–3104, http://doi.org/10.1128/JCM.01537-15.
Brossier, F., Sougakoff, W., Bernard, C., Petrou, M., Adeyema, K., Pham, A., Amy de la Breteque, D., Vallet, M., Jarlier, V., Sola, C. and Veziris, N. (2015). Molecular Analysis of the embCAB Locus and embR Gene Involved in Ethambutol Resistance in Clinical Isolates of Mycobacterium tuberculosis in France. Antimicrobial Agents and Chemotherapy 59, 4800–4808, http://doi.org/10.1128/AAC.00150-15.
Bui, T. V., Lévy-Bruhl, D., Che, D., Antoine, D., Jarlier, V. and Robert, J. (2015). Impact of the BCG vaccination policy on tuberculous meningitis in children under 6 years in metropolitan France between 2000 and 2011. Euro Surveill 20.
Cambau, E., Viveiros, M., Machado, D., Raskine, L., Ritter, C., Tortoli, E., Matthys, V., Hoffner, S., Richter, E., Perez Del Molino, M. L., Cirillo, D. M., van Soolingen, D. and Bottger, E. C. (2015). Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study. Journal of Antimicrobial Chemotherapy 70, 686–696, http://doi.org/10.1093/jac/dku438.
Catho, G., Couraud, S., Grard, S., Bouaziz, A., Sénéchal, A., Valour, F., Perpoint, T., Braun, E., Biron, F., Ferry, T., Chidiac, C., Freymond, N., Perrot, E., Souquet, P.-J., Maury, J.-M., Tronc, F., Veziris, N., Lina, G., Dumitrescu, O. and Ader, F. (2015). Management of emerging multidrug-resistant tuberculosis in a low-prevalence setting. Clinical Microbiology and Infection 21, 472.e7-472.e10, http://doi.org/10.1016/j.cmi.2014.12.022.
Coolen, N., Morand, P., Martin, C., Hubert, D., Kanaan, R., Chapron, J., Honoré, I., Dusser, D., Audureau, E., Veziris, N. and Burgel, P.-R. (2015). Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin. Journal of Cystic Fibrosis 14, 594–599, http://doi.org/10.1016/j.jcf.2015.02.006.
Grard, S., Catho, G., Valour, F., Bouaziz, A., Perpoint, T., Braun, E., Biron, F., Miailhes, P., Ferry, T., Chidiac, C., Souquet, P.-J., Couraud, S., Lina, G., Goutelle, S., Veziris, N., Dumitrescu, O. and Ader, F. (2015). Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four? Open Forum Infectious Diseases 2, ofv175, http://doi.org/10.1093/ofid/ofv175.
Guglielmetti, L. and Robert, J. (2015). Bédaquiline : de l’in vitro aux essais cliniques d’un nouvel antituberculeux. Journal des Anti-infectieux 17, 60–66, http://doi.org/10.1016/j.antinf.2014.12.003.
Guglielmetti, L., Mougari, F., Lopes, A., Raskine, L. and Cambau, E. (2015). Human infections due to nontuberculous mycobacteria: the infectious diseases and clinical microbiology specialists’ point of view. Future Microbiology 10, 1467–1483, http://doi.org/10.2217/fmb.15.64.
Guglielmetti, L., Dû, D. L., Jachym, M., Henry, B., Martin, D., Caumes, Eric, Veziris, Nicolas, Métivier, N., Robert, J., Andrejak, C., Bernard, C., Brossier, F., Chadelat, K., Dautzenberg, B., Jarlier, V., Raskine, L., Rivoire, B., Veziris, N., Appere, C., Assouline, P., Borie, R., Boukari, L., Caseris, M., Caumes, E., Douadi, Y., Dumoulin, J., Duval, C., Faucher, J. F., Gallien, S., Godet, C., Grusse, J. L., Lopes, A., Meynard, J. L., Naccache, J. M., Philippe, B., Richaud, C. and Saad, H. (2015). Compassionate Use of Bedaquiline for the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Interim Analysis of a French Cohort. Clin Infect Dis 60, 188–194, http://doi.org/10.1093/cid/ciu786.
Hervé, C., Bergot, E., Veziris, N. and Blanc, F.-X. (2015). La tuberculose en 2015 : du diagnostic à la détection des formes résistantes. Revue des Maladies Respiratoires 32, 784–790, http://doi.org/10.1016/j.rmr.2015.06.008.
Isaakidis, P., Casas, E. C., Das, M., Tseretopoulou, X., Ntzani, E. E. and Ford, N. (2015). Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis. The International Journal of Tuberculosis and Lung Disease 19, 969–978, http://doi.org/10.5588/ijtld.15.0123.
Jaubert, J., Mougari, F., Picot, S., Boukerrou, M., Barau, G., Ali Ahmed, S.-A., Raskine, L., Camuset, G., Michault, A., Simac, C. and Cambau, E. (2015). A case of postoperative breast infection by Mycobacterium fortuitum associated with the hospital water supply. American Journal of Infection Control 43, 406–408, http://doi.org/10.1016/j.ajic.2014.12.023.
Kibleur, Y. and Veziris, N. (2015). French Nationwide Cohort Temporary Utilization Authorization Survey of GranuPAS® in MDR-TB Patients. Chemotherapy 60, 174–179, http://doi.org/10.1159/000371869.
Reibel, F., Cambau, E. and Aubry, A. (2015). Histoire et actualité du traitement de la lèpre. Journal des Anti-Infectieux 17, 91–98, http://doi.org/10.1016/j.antinf.2015.01.004.
Reibel, F., Cambau, E. and Aubry, A. (2015). Update on the epidemiology, diagnosis, and treatment of leprosy. Médecine et Maladies Infectieuses 45, 383–393, http://doi.org/10.1016/j.medmal.2015.09.002.
Reibel, F., Chauffour, A., Brossier, F., Jarlier, V., Cambau, E. and Aubry, A. (2015). New Insights into the Geographic Distribution of Mycobacterium leprae SNP Genotypes Determined for Isolates from Leprosy Cases Diagnosed in Metropolitan France and French Territories Ed. Johnson, C. PLOS Neglected Tropical Diseases 9, e0004141, http://doi.org/10.1371/journal.pntd.0004141.
Renvoisé, A., Brossier, F., Galati, E., Veziris, N., Sougakoff, W., Aubry, A., Robert, J., Cambau, E., Jarlier, V. and Bernard, C. (2015). Assessing Primary and Secondary Resistance to Clarithromycin and Amikacin in Infections Due to Mycobacterium avium Complex. Antimicrobial Agents and Chemotherapy 59, 7153–7155, http://doi.org/10.1128/AAC.01027-15.
Robert, J. and CNR-MyRMA (2015). Résistance aux antituberculeux en France en 2013. Bulletin Epidémiologique Hebdomadaire 9–10, 172–174, URL: http://www.invs.sante.fr/beh/2015/9-10/pdf/2015_9-10_4.pdf.
Roux, A.-L., Catherinot, E., Soismier, N., Heym, B., Bellis, G., Lemonnier, L., Chiron, R., Fauroux, B., Le Bourgeois, M., Munck, A., Pin, I., Sermet, I., Gutierrez, C., Veziris, N., Jarlier, V., Cambau, E., Herrmann, J.-L., Guillemot, D. and Gaillard, J.-L. (2015). Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients. Journal of Cystic Fibrosis 14, 63–69, http://doi.org/10.1016/j.jcf.2014.07.004.

Publications du CNR en 2016

Bernard, J., Armand-Lefèvre, L., Luce, E., Mniai, A. E., Chau, F., Casalino, E., Andremont, A. and Ruppé, E. (2016). Impact of a short exposure to levofloxacin on faecal densities and relative abundance of total and quinolone-resistant Enterobacteriaceae. Clinical Microbiology and Infection 22, 646.e1-646.e4, http://doi.org/10.1016/j.cmi.2016.04.015.
Bernard, C., Aubry, A., Chauffour, A., Brossier, F., Robert, J. and Veziris, N. (2016). In vivo Mycobacterium tuberculosis fluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests. J Antimicrob Chemother, http://doi.org/10.1093/jac/dkw344.
Brossier, F. and Aubry, A. (2016). Résistance de Mycobacterium tuberculosis aux antituberculeux. Feuillets Bio 328, 17–25, http://doi.org/10.1684/abc.2016.1132.
Brossier, F., Guindo, D., Pham, A., Reibel, F., Sougakoff, W., Veziris, N. and Aubry, A. (2016). Performance of the New Version (v2.0) of the GenoType MTBDRsl Test for Detection of Resistance to Second-Line Drugs in Multidrug-Resistant Mycobacterium tuberculosis Complex Strains. J Clin Microbiol 54, 1573–1580, http://doi.org/10.1128/JCM.00051-16.
Brossier, F., Cambau, E., Tessier, E., Jarlier, V. and Sougakoff, W. (2016). The in vitro mechanisms of isoniazid and ethionamide resistance poorly reflect those in vivo in Mycobacterium tuberculosis. Tuberculosis 101, 144–145, http://doi.org/10.1016/j.tube.2016.09.028.
Brossier, F., Boudinet, M., Jarlier, V., Petrella, S. and Sougakoff, W. (2016). Comparative study of enzymatic activities of new KatG mutants from low- and high-level isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Tuberculosis 100, 15–24, http://doi.org/10.1016/j.tube.2016.06.002.
Chauffour, A., Robert, J., Veziris, N., Aubry, A. and Jarlier, V. (2016). Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium ulcerans Infection in Mice. PLOS Neglected Tropical Diseases 10, e0005066, http://doi.org/10.1371/journal.pntd.0005066.
Chazel, M., Marchandin, H., Keck, N., Terru, D., Carrière, C., Ponsoda, M., Jacomo, V., Panteix, G., Bouzinbi, N., Bañuls, A.-L., Choisy, M., Solassol, J., Aubry, A. and Godreuil, S. (2016). Evaluation of the SLOMYCO Sensititre® panel for testing the antimicrobial susceptibility of Mycobacterium marinum isolates. Annals of Clinical Microbiology and Antimicrobials 15, 30, http://doi.org/10.1186/s12941-016-0145-1.
Crabol, Y., Catherinot, E., Veziris, N., Jullien, V. and Lortholary, O. (2016). Rifabutin: where do we stand in 2016? J Antimicrob Chemother dkw024, http://doi.org/10.1093/jac/dkw024.
Fox, G. J., Benedetti, A., Mitnick, C. D., Pai, M., Menzies, D. and Mdr-Tb, T. C. G. for M.-A. of I. P. D. in (2016). Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis. PLOS ONE 11, e0151724, http://doi.org/10.1371/journal.pone.0151724.
Fox, G. J., Mitnick, C. D., Benedetti, A., Chan, E. D., Becerra, M., Chiang, C.-Y., Keshavjee, S., Koh, W.-J., Shiraishi, Y., Viiklepp, P., Yim, J.-J., Pasvol, G., Robert, J., Shim, T. S., Shin, S. S., Menzies, Dick, Mdr-Tb, for the C. G. for M.-A. of I. P. D. in, Ahuja, S., Ashkin, D., Avendaño, M., Banerjee, R., Bauer, M., Burgos, M., Centis, R., Cobelens, F., Cox, H., D’Ambrosio, L., Lange, W. C. M. de, DeRiemer, K., Enarson, D., Falzon, D., Flanagan, K., Flood, J., Gandhi, N., Garcia-Garcia, L., Granich, R. M., Hollm-Delgado, M. G., Holtz, T. H., Hopewell, P., Iseman, M., Jarlsberg, L. G., Kim, H. R., Lancaster, J., Lange, C., Leimane, V., Leung, C. C., Li, J., Menzies, D., Migliori, G. B., Narita, M., Nathanson, E., Odendaal, R., O’Riordan, P., Pai, M., Palmero, D., Park, S. K., Pena, J., Pérez-Guzmán, C., Ponce-de-Leon, A., Quelapio, M. I. D., Quy, H. T., Riekstina, V., Royce, S., Salim, M., Schaaf, H. S., Seung, K. J., Shah, L., Shean, K., Sifuentes-Osornio, J., Sotgiu, G., Strand, M. J., Sung, S. W., Tabarsi, P., Tupasi, T. E., Vargas, M. H., Altena, R. van, Walt, M. van der, Werf, T. S. van der, Westenhouse, J. and Yew, W. W. (2016). Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis. Clin Infect Dis 62, 887–895, http://doi.org/10.1093/cid/ciw002.
Guglielmetti, L., Dû, D. L., Veziris, N., Caumes, E., Marigot-Outtandy, D., Yazdanpanah, Y., Robert, J. and Fréchet-Jachym, M. (2016). Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? European Respiratory Journal 48, 582–585, http://doi.org/10.1183/13993003.00411-2016.
Henry, B., Revest, M., Dournon, N., Epelboin, L., Mellon, G., Bellaud, G., Mordant, P., Le Dû, D., Véziris, N., Bernard, C., Morel, S., Jauréguiberry, S., Michelet, C., Bricaire, F., Tattevin, P. and Caumes, É. (2016). Preliminary Favorable Outcome for Medically and Surgically Managed Extensively Drug-Resistant Tuberculosis, France, 2009–2014. Emerging Infectious Diseases 22, 518–521, http://doi.org/10.3201/eid2203.151130.
Lachâtre, M., Rioux, C., Dû, D. L., Fréchet-Jachym, M., Veziris, N., Bouvet, E. and Yazdanpanah, Y. (2016). Bedaquiline plus delamanid for XDR tuberculosis. Lancet Infect Dis 16, 294, http://doi.org/10.1016/S1473-3099(16)00047-5.
Lafeuille, E., Veziris, N., Sougakoff, W., Roure, F., Le Dû, D., Dournon, N., Caumes, E., Jarlier, V., Aubry, A., Robert, J. and Bernard, C. (2016). XDR-tuberculosis in France: Community transmission due to non-compliance with isolation precautions. Médecine et Maladies Infectieuses 46, 52–55, http://doi.org/10.1016/j.medmal.2015.12.008.
Lange, C., Duarte, R., Fréchet-Jachym, M., Guenther, G., Guglielmetti, L., Olaru, I. D., Oliveira, O., Rumetshofer, R., Veziris, N. and van Leth, F. (2016). Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe. Am J Respir Crit Care Med 194, 1029–1031, http://doi.org/10.1164/rccm.201606-1097LE.
Lortholary, O., Roussillon, C., Boucherie, C., Padoin, C., Chaix, M.-L., Breton, G., Rami, A., Veziris, N., Patey, O., Caumes, E., May, T., Molina, J.-M., Robert, J., Tod, M., Fagard, C. and Chêne, G. (2016). Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial. Journal of Antimicrobial Chemotherapy 71, 783–793, http://doi.org/10.1093/jac/dkv384.
Mieras, L., Anthony, R., van Brakel, W., Bratschi, M. W., van den Broek, J., Cambau, E., Cavaliero, A., Kasang, C., Perera, G., Reichman, L., Richardus, J. H., Saunderson, P., Steinmann, P. and Yew, W. W. (2016). Negligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosy. Infectious Diseases of Poverty 5, 46, http://doi.org/10.1186/s40249-016-0140-y.
Mougari, F., Amarsy, R., Veziris, N., Bastian, S., Brossier, F., Berçot, B., Raskine, L. and Cambau, E. (2016). Standardized interpretation of antibiotic susceptibility testing and resistance genotyping for Mycobacterium abscessus with regard to subspecies and erm41 sequevar. J Antimicrob Chemother 71, 2208–2212, http://doi.org/10.1093/jac/dkw130.
Mougari, F., Guglielmetti, L., Raskine, L., Sermet-Gaudelus, I., Veziris, N. and Cambau, E. (2016). Infections caused by Mycobacterium abscessus: epidemiology, diagnostic tools and treatment. Expert Review of Anti-infective Therapy 14, 1139–1154, http://doi.org/10.1080/14787210.2016.1238304.
Pantel, A., Petrella, S., Veziris, N., Matrat, S., Bouige, A., Ferrand, H., Sougakoff, W., Mayer, C. and Aubry, A. (2016). Description of compensatory gyrA mutations restoring fluoroquinolone susceptibility in Mycobacterium tuberculosis. J Antimicrob Chemother 71, 2428–2431, http://doi.org/10.1093/jac/dkw169.
Parize, P., Hamelin, A., Veziris, N., Morand, P. C., Guillemain, R., Lortholary, O. and Dupin, N. (2016). Induction therapy with linezolid/clarithromycin combination for Mycobacterium chelonae skin infections in immunocompromised hosts. Journal of the European Academy of Dermatology and Venereology 30, 101–105, http://doi.org/10.1111/jdv.12965.
Raharolahy, O., Ramarozatovo, L. S., Ranaivo, I. M., Sendrasoa, F. A., Andrianarison, M., Andrianarivelo, M. R., Cambau, E. and Rabenja, F. R. (2016). A Case of Fluoroquinolone-Resistant Leprosy Discovered after 9 Years of Misdiagnosis. Case Reports in Infectious Diseases 2016, 4632369, http://doi.org/10.1155/2016/4632369.

Publications du CNR en 2017

Allerberger, F., Cambau, E. and Lange, C. (2017). Joint efforts urgently needed at times of emerging tuberculosis drug resistance. Clinical Microbiology and Infection 23, 129–130, http://doi.org/10.1016/j.cmi.2016.08.023.
Andre, E., Goeminne, L., Cabibbe, A., Beckert, P., Mukadi, B. K., Mathys, V., Gagneux, S., Niemann, S., Ingen, J. V. and Cambau, E. (2017). Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria. Clinical Microbiology and Infection 23, 167–172, http://doi.org/10.1016/j.cmi.2016.09.006.
Appelgren, A., Morquin, D., Dufour, S., Le Moing, V., Reynes, J., Lotthé, A., Parer, S., Corbeau, C., Aubry, A., Sougakoff, W., Solassol, J., Bonzon, L., Dumont, Y. and Godreuil, S. (2017). Investigation of pre-XDR Beijing Mycobacterium tuberculosis transmission to a healthcare worker in France, 2016. Journal of Hospital Infection, http://doi.org/10.1016/j.jhin.2017.06.030.
Aubry, A., Mougari, F., Reibel, F. and Cambau, E. (2017). Mycobacterium marinum. Microbiology Spectrum 5, http://doi.org/10.1128/microbiolspec.TNMI7-0038-2016.
Bouchet, F., Martin, B., Aubry, A., Veziris, N., Lavigne, J.-P. and Sotto, A. (2017). Should single antibiotic therapy be avoided for nontuberculous mycobacteria? Médecine et Maladies Infectieuses, http://doi.org/10.1016/j.medmal.2017.07.004.
Brossier, F. and Sougakoff, W. (2017). Molecular detection methods of resistance to antituberculosis drugs in Mycobacterium tuberculosis. Médecine et Maladies Infectieuses 47, 340–348, http://doi.org/10.1016/j.medmal.2017.04.008.
Brossier, F., Pham, A., Bernard, C., Aubry, A., Jarlier, V., Veziris, N., Sougakoff, W. and CNR-MyRMA, O. B. of T. (2017). Molecular Investigation of Resistance to Second-Line Injectable Drugs in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis in France. Antimicrob Agents Chemother 61, e01299-16, http://doi.org/10.1128/AAC.01299-16.
Delafont, V., Samba-Louaka, A., Cambau, E., Bouchon, D., Moulin, L. and Héchard, Y. (2017). Mycobacterium llatzerense, a waterborne Mycobacterium, that resists phagocytosis by Acanthamoeba castellanii. Scientific Reports 7, 46270, http://doi.org/10.1038/srep46270.
Fournier, A., Bernard, C., Sougakoff, W., Quelet, S., Antoun, F., Charlois-Ou, C., Dormant, I., Dufour, M.-O., Hocine, N., Jarlier, V. and Veziris, N. (2017). Neither genotyping nor contact tracing allow correct understanding of multidrug-resistant tuberculosis transmission. European Respiratory Journal 50, 1700891, http://doi.org/10.1183/13993003.00891-2017.
Guglielmetti, L., Jaspard, M., Dû, D. L., Lachâtre, M., Marigot-Outtandy, D., Bernard, C., Veziris, N., Robert, J., Yazdanpanah, Y., Caumes, E. and Fréchet-Jachym, M. (2017). Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. European Respiratory Journal 49, 1601799, http://doi.org/10.1183/13993003.01799-2016.
Guglielmetti, L., Hewison, C., Avaliani, Z., Hughes, J., Kiria, N., Lomtadze, N., Ndjeka, N., Setkina, S., Shabangu, A., Sikhondze, W., Skrahina, A., Veziris, N. and Furin, J. (2017). Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries. The International Journal of Tuberculosis and Lung Disease 21, 167–174, http://doi.org/10.5588/ijtld.16.0493.
Jaspard, M., Elefant-Amoura, E., Melonio, I., de Montgolfier, I., Veziris, N. and Caumes, E. (2017). Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman. Emerging Infect Dis 23, http://doi.org/10.3201/eid2310.161398.
Leyer, C., Gregorowicz, G., Mougari, F., Raskine, L., Cambau, E. and Briel, D. de (2017). Comparison of Saramis 4.12 and IVD 3.0 Vitek MS Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry for Identification of Mycobacteria from Solid and Liquid Culture Media. Journal of Clinical Microbiology 55, 2045–2054, http://doi.org/10.1128/JCM.00006-17.
Maitre, T., Aubry, A. and Veziris, N. (2017). Molecular Drug-Susceptibility Test for Tuberculosis. New England Journal of Medicine 377, 2403–2404, http://doi.org/10.1056/NEJMc1714218.
Maitre, T., Petitjean, G., Chauffour, A., Bernard, C., El Helali, N., Jarlier, V., Reibel, F., Chavanet, P., Aubry, A. and Veziris, N. (2017). Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis? J Antimicrob Chemother 72, 2326–2333, http://doi.org/10.1093/jac/dkx150.
Maitre, T., Aubry, A., Jarlier, V., Robert, J., Veziris, N., Bernard, C., Sougakoff, W., Brossier, F., Cambau, E., Mougari, F. and Raskine, L. (2017). Multidrug and extensively drug-resistant tuberculosis. Médecine et Maladies Infectieuses 47, 3–10, http://doi.org/10.1016/j.medmal.2016.07.006.
Mazoyer, A., Ycart, B. and Veziris, N. (2017). Correction: Unbiased Estimation of Mutation Rates under Fluctuating Final Counts. PLOS ONE 12, e0173143, http://doi.org/10.1371/journal.pone.0173143.
Mougari, F., Loiseau, J., Veziris, N., Bernard, C., Bercot, B., Sougakoff, W., Jarlier, V., Raskine, L. and Cambau, E. (2017). Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria. J Antimicrob Chemother 72, 1669–1677, http://doi.org/10.1093/jac/dkx021.
Mougari, F., Bouziane, F., Crockett, F., Nessar, R., Chau, F., Veziris, N., Sapriel, G., Raskine, L. and Cambau, E. (2017). Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies. Antimicrob Agents Chemother 61, e00943-16, http://doi.org/10.1128/AAC.00943-16.
Schön, T., Miotto, P., Köser, C. U., Viveiros, M., Böttger, E. and Cambau, E. (2017). Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives. Clinical Microbiology and Infection 23, 154–160, http://doi.org/10.1016/j.cmi.2016.10.022.
Veziris, N., Bernard, C., Guglielmetti, L., Du, D. L., Marigot-Outtandy, D., Jaspard, M., Caumes, E., Lerat, I., Rioux, C., Yazdanpanah, Y., Tiotiu, A., Lemaitre, N., Brossier, F., Jarlier, V., Robert, J., Sougakoff, W. and Aubry, A. (2017). Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors. European Respiratory Journal 49, 1601719, http://doi.org/10.1183/13993003.01719-2016.
Wyplosz, B., Mougari, F., Rawi, M. A., Baillon, C., Marigot-Outtandy, D., Dû, D. L., Jachym, M., Hervé, V., Raskine, L. and Cambau, E. (2017). Visualizing viable Mycobacterium tuberculosis in sputum to monitor isolation measures. Journal of Infection 74, 207–210, http://doi.org/10.1016/j.jinf.2016.11.014.

Publications du CNR en 2018

Ahmad, N., Ahuja, S. D., Akkerman, O. W., Alffenaar, J.-W. C., Anderson, L. F., Baghaei, P., Bang, D., Barry, P. M., Bastos, M. L., Behera, D., Benedetti, A., Bisson, G. P., Boeree, M. J., Bonnet, M., Brode, S. K., Brust, J. C. M., Cai, Y., Caumes, E., Cegielski, J. P., Centis, R., Chan, P.-C., Chan, E. D., Chang, K.-C., Charles, M., Cirule, A., Dalcolmo, M. P., D’Ambrosio, L., de Vries, G., Dheda, K., Esmail, A., Flood, J., Fox, G. J., Fréchet-Jachym, M., Fregona, G., Gayoso, R., Gegia, M., Gler, M. T., Gu, S., Guglielmetti, L., Holtz, T. H., Hughes, J., Isaakidis, P., Jarlsberg, L., Kempker, R. R., Keshavjee, S., Khan, F. A., Kipiani, M., Koenig, S. P., Koh, W.-J., Kritski, A., Kuksa, L., Kvasnovsky, C. L., Kwak, N., Lan, Z., Lange, C., Laniado-Laborín, R., Lee, M., Leimane, V., Leung, C.-C., Leung, E. C.-C., Li, P. Z., Lowenthal, P., Maciel, E. L., Marks, S. M., Mase, S., Mbuagbaw, L., Migliori, G. B., Milanov, V., Miller, A. C., Mitnick, C. D., Modongo, C., Mohr, E., Monedero, I., Nahid, P., Ndjeka, N., O’Donnell, M. R., Padayatchi, N., Palmero, D., Pape, J. W., Podewils, L. J., Reynolds, I., Riekstina, V., Robert, J., Rodriguez, M., Seaworth, B., Seung, K. J., Schnippel, K., Shim, T. S., Singla, R., Smith, S. E., Sotgiu, G., Sukhbaatar, G., Tabarsi, P., Tiberi, S., Trajman, A., Trieu, L., Udwadia, Z. F., van der Werf, T. S., Veziris, N., Viiklepp, P., Vilbrun, S. C., Walsh, K., Westenhouse, J., Yew, W.-W., Yim, J.-J., Zetola, N. M., Zignol, M. and Menzies, D. (2018). Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. The Lancet 392, 821–834, http://doi.org/10.1016/S0140-6736(18)31644-1.
Ates, L. S., Dippenaar, A., Sayes, F., Pawlik, A., Bouchier, C., Ma, L., Warren, R. M., Sougakoff, W., Majlessi, L., van Heijst, J. W. J., Brossier, F. and Brosch, R. (2018). Unexpected Genomic and Phenotypic Diversity of Mycobacterium africanum Lineage 5 Affects Drug Resistance, Protein Secretion, and Immunogenicity. Genome Biol Evol 10, 1858–1874, http://doi.org/10.1093/gbe/evy145.
Bastard, M., Guglielmetti, L., Huerga, H., Hayrapetyan, A., Khachatryan, N., Yegiazaryan, L., Faqirzai, J., Hovhannisyan, L., Varaine, F. and Hewison, C. (2018). Bedaquiline and Repurposed Drugs for Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: How Much Better Are They? Am J Respir Crit Care Med 198, 1228–1231, http://doi.org/10.1164/rccm.201801-0019LE.
Bergot, E., Abiteboul, D., Andréjak, C., Antoun, F., Barras, E., Blanc, F.-X., Bourgarit, A., Charlois-Ou, C., Delacourt, C., Dirou, S., Gerin, M., Guerin, S., Haustraete, É., Henry, B., Lucet, J.-C., Maitre, T., Morin, J., Le Palud, P., Pommelet, V., Rivoisy, C., Robert, J., Veziris, N. and Herrmann, J.-L. (2018). [Practice recommendations for the use and interpretation of interferon gamma release assays in the diagnosis of latent and active tuberculosis]. Rev Mal Respir 35, 852–858, http://doi.org/10.1016/j.rmr.2018.08.007.
Blanc, F.-X., Dirou, S., Morin, J. and Veziris, N. (2018). [Interferon gamma release assay tests for the diagnosis of active tuberculosis]. Rev Mal Respir 35, 894–899, http://doi.org/10.1016/j.rmr.2018.08.016.
Cambau, E. (2018). Antileprosy drugs: mode of action and mechanisms. In: International textbook of leprosy, URL: https://internationaltextbookofleprosy.org/chapter/anti-leprosy-drugs-modes-action-and-mechanisms-resistance-mycobacterium-leprae [Accessed May 2022].
Cambau, E., Saunderson, P., Matsuoka, M., Cole, S. T., Kai, M., Suffys, P., Rosa, P. S., Williams, D., Gupta, U. D., Lavania, M., Cardona-Castro, N., Miyamoto, Y., Hagge, D., Srikantam, A., Hongseng, W., Indropo, A., Vissa, V., Johnson, R. C., Cauchoix, B., Pannikar, V. K., Cooreman, E. a. W. D., Pemmaraju, V. R. R., Gillini, L., Kriswamati, A., Al-Samie, A. R., Issoufou, A., Tiendrebeogo, A., Kingalu, A., Randrianantoandro, A., Kumar, A., Chauffour, A., Win, A. A., Pandey, B., Agrawal, C. M., Widaningrum, C., Schmotzer, C., Kafando, C., Bhandari, C. M., Sema, C., Vidanagama, D. S., Scollard, D. M., Beyene, D., Morelo, E. F., Kassa, E. D., Ramarolahy, E. B., Claco, E., Villalon, E. E., Sidibe, F., Sakho, F., Abdoulaye, F., Guilengue, F. F., Gajete, F., Babu, G. R., Moussa, G., Thakur, G. D., Cabanos, G., Sock, G., Clugston, G., Zaidy, H., Watanabe, H., Kawuma, H. J., Mallari, I. B., Goulart, I. M. B., Ahamed, I., Subbanna, J., Houzeo, J. G., Luengu, J. N. M., Bertolli, J., Lloyd-Owen, J., Matheu, J., Brunelli, J. P., Alzate, J. C. B., Neupane, Kapil Dev, Osuga, K., Yamaguchi, K., Azam, K., Lin, K. M., Momoudu, K., Kyaw, K., Bide, L., Doanh, L. H., My, L. H., Shah, M., Kodio, M., Sidibe, M., Ebenezer, M., Grossi, M. A. de F., Balagon, M. F., Canlonon, M., Makino, M., Htoo, M. M., Ahmed, M. J., Nadine, M.-M., Roferos, F. O., Krismawati, H., Thida, M., Htoon, M. T., Neupane, K. D., Phuc, N. H. N., Van, N. H., Hai, N. P. N., Ishii, N., Soe, O., Amiel, O., Tossou, O., Konare, O., Joshi, P. L., Rao, P. V. R., Krishnamurthy, P., Brennan, P. J., Busso, P., Bhatia, R., Andrianarivelo, M. R., Ramdas, D. R., Chabi, R., Gusmao, R., DjupuriIzwardy, R., Soares, R. C. F. R., Jhadav, R., Buhrer, S., Cho, S.-N. R., Jianping, S., Lzumi, S., Barua, S., Chaitanya, S., Tiendrebeogo, S. M. R., Khang, T. H., Gillis, T. P., Mori, T., Vijayalakshmi, V., Kamara, V. D., Wei, W., Smith, W. C. S., Li, W., Lew, W., Al-Qubati, Y., Suzuki, Y. and Nanba, Y. (2018). Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009–15. Clinical Microbiology and Infection 24, 1305–1310, http://doi.org/10.1016/j.cmi.2018.02.022.
Chauffour, A., Lecorche, E., Reibel, F., Mougari, F., Raskine, L., Aubry, A., Jarlier, V. and Cambau, E. (2018). Prospective study on antimicrobial resistance in leprosy cases diagnosed in France from 2001 to 2015. Clinical Microbiology and Infection 24, 1213.e5-1213.e8, http://doi.org/10.1016/j.cmi.2018.06.004.
Coolen-Allou, N., Touron, T., Belmonte, O., Gazaille, V., Andre, M., Allyn, J., Picot, S., Payet, A. and Veziris, N. (2018). Clinical, Radiological, and Microbiological Characteristics of Mycobacterium simiae Infection in 97 Patients. Antimicrobial Agents and Chemotherapy 62, e00395-18, http://doi.org/10.1128/AAC.00395-18.
D’Ambrosio, L., Bothamley, G., Caminero Luna, J. A., Duarte, R., Guglielmetti, L., Muñoz Torrico, M., Payen, M. C., Saavedra Herrera, N., Salazar Lezama, M. A., Skrahina, A., Tadolini, M., Tiberi, S., Veziris, N. and Migliori, G. B. (2018). Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond. Pulmonology 24, 132–141, http://doi.org/10.1016/j.rppnen.2017.10.005.
Gras, J., De Castro, N., Montlahuc, C., Champion, L., Scemla, A., Matignon, M., Lachâtre, M., Raskine, L., Grall, N., Peraldi, M. N. and Molina, J. M. (2018). Clinical characteristics, risk factors, and outcome of tuberculosis in kidney transplant recipients: A multicentric case-control study in a low-endemic area. Transplant Infectious Disease 20, e12943, http://doi.org/10.1111/tid.12943.
Griffith, D. E., Eagle, G., Thomson, R., Aksamit, T. R., Hasegawa, N., Morimoto, K., Addrizzo-Harris, D. J., O’Donnell, A. E., Marras, T. K., Flume, P. A., Loebinger, M. R., Morgan, L., Codecasa, L. R., Hill, A. T., Ruoss, S. J., Yim, J.-J., Ringshausen, F. C., Field, S. K., Philley, J. V., Wallace, R. J., van Ingen, J., Coulter, C., Nezamis, J. and Winthrop, K. L. (2018). Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med 198, 1559–1569, http://doi.org/10.1164/rccm.201807-1318OC.
Guglielmetti, L., Barkane, L., Dû, D. L., Marigot-Outtandy, D., Robert, J., Veziris, N., Yazdanpanah, Y., Kuksa, L., Caumes, E. and Fréchet-Jachym, M. (2018). Safety and efficacy of exposure to bedaquiline−delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia. European Respiratory Journal 51, 1702550, http://doi.org/10.1183/13993003.02550-2017.
Guglielmetti, L., Tiberi, S., Burman, M., Kunst, H., Wejse, C., Togonidze, T., Bothamley, G. and Lange, C. (2018). QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study. European Respiratory Journal 52, http://doi.org/10.1183/13993003.00537-2018.
Guglielmetti, L., Veziris, N., Aubry, A., Brossier, F., Bernard, C., Sougakoff, W., Jarlier, V., Robert, J. and surveillance, for the L. N. for M. (2018). Risk factors for extensive drug resistance in multidrug-resistant tuberculosis cases: a case-case study., doi:info:doi/10.5588/ijtld.17.0387.
Kouriba, B., Ouwe Missi Oukem-Boyer, O., Traoré, B., Touré, A., Raskine, L. and Babin, F. X. (2018). Installing biosafety level 3 containment laboratories in low- and middle-income countries: challenges and prospects from Mali’s experience. New Microbes New Infect 26, S74–S77, http://doi.org/10.1016/j.nmni.2018.05.011.
Lecorche, E., Haenn, S., Mougari, F., Kumanski, S., Veziris, N., Benmansour, H., Raskine, L., Moulin, L., Cambau, E., Aubry, A., Brossier, F., Chauffour, A., Jaffre, J., Jarlier, V., Robert, J. and Sougakoff, W. (2018). Comparison of methods available for identification of Mycobacterium chimaera. Clinical Microbiology and Infection 24, 409–413, http://doi.org/10.1016/j.cmi.2017.07.031.
Levi, L. I., Schlemmer, F., de Castro, N., Brun, O., Veziris, N., Argemi, X., Roupret, M., Launay, O., Bergeron, A. and Groh, M. (2018). Bacillus Calmette-Guerin infection following intravesical instillation: Does the strain matter? Médecine et Maladies Infectieuses, http://doi.org/10.1016/j.medmal.2018.11.014.
Machado, D., Lecorche, E., Mougari, F., Cambau, E. and Viveiros, M. (2018). Insights on Mycobacterium leprae Efflux Pumps and Their Implications in Drug Resistance and Virulence. Front Microbiol 9, http://doi.org/10.3389/fmicb.2018.03072.
Maitre, T., Robert, J. and Veziris, N. (2018). Introduction: épidémiologie de la tuberculose et de l’infection tuberculeuse latente. Rev Mal Respir 35, 859–861, http://doi.org/10.1016/j.rmr.2018.08.009.
Mieras, L. F., Taal, A. T., van Brakel, W. H., Cambau, E., Saunderson, P. R., Smith, W. C. S., Prakoeswa, C. R. S., Astari, L., Scollard, D. M., do Nascimento, D. C., Grosset, J., Kar, H. K., Izumi, S., Gillini, L., Virmond, M. C. L. and Sturkenboom, M. G. G. (2018). An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP++. BMC Infectious Diseases 18, 506, http://doi.org/10.1186/s12879-018-3402-4.
Rueda, D., Bernard, C., Gandy, L., Capton, E., Boudjelloul, R., Brossier, F., Veziris, N., Zimic, M. and Sougakoff, W. (2018). Estimation of pyrazinamidase activity using a cell-free In vitro synthesis of pnca and its association with pyrazinamide susceptibility in Mycobacterium tuberculosis. Int J Mycobacteriol 7, 16–25, http://doi.org/10.4103/ijmy.ijmy_187_17.
Sayes, F., Blanc, C., Ates, L. S., Deboosere, N., Orgeur, M., Le Chevalier, F., Gröschel, M. I., Frigui, W., Song, O.-R., Lo-Man, R., Brossier, F., Sougakoff, W., Bottai, D., Brodin, P., Charneau, P., Brosch, R. and Majlessi, L. (2018). Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors. Cell Reports 23, 1072–1084, http://doi.org/10.1016/j.celrep.2018.03.125.
Scherr, N., Bieri, R., Thomas, S. S., Chauffour, A., Kalia, N. P., Schneide, P., Ruf, M.-T., Lamelas, A., Manimekalai, M. S. S., Grüber, G., Ishii, N., Suzuki, K., Tanner, M., Moraski, G. C., Miller, M. J., Witschel, M., Jarlier, V., Pluschke, G. and Pethe, K. (2018). Targeting the Mycobacterium ulcerans cytochrome bc 1 : aa 3 for the treatment of Buruli ulcer. Nature Communications 9, 5370, http://doi.org/10.1038/s41467-018-07804-8.
van Ingen, J., Aksamit, T., Andrejak, C., Böttger, E. C., Cambau, E., Daley, C. L., Griffith, D. E., Guglielmetti, L., Holland, S. M., Huitt, G. A., Koh, W.-J., Lange, C., Leitman, P., Marras, T. K., Morimoto, K., Olivier, K. N., Santin, M., Stout, J. E., Thomson, R., Tortoli, E., Wallace, R. J., Winthrop, K. L. and Wagner, D. (2018). Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. European Respiratory Journal 51, 1800170, http://doi.org/10.1183/13993003.00170-2018.
Walker, T. M., Merker, M., Knoblauch, A. M., Helbling, P., Schoch, O. D., Werf, M. J. van der, Kranzer, K., Fiebig, L., Kröger, S., Haas, W., Hoffmann, H., Indra, A., Egli, A., Cirillo, D. M., Robert, J., Rogers, T. R., Groenheit, R., Mengshoel, A. T., Mathys, V., Haanperä, M., Soolingen, D. van, Niemann, S., Böttger, E. C., Keller, P. M., Avsar, K., Bauer, C., Bernasconi, E., Borroni, E., Brusin, S., Dévis, M. C., Crook, D. W., Dedicoat, M., Fitzgibbon, M., Gagneux, S., Geiger, F., Guthmann, J.-P., Hendrickx, D., Hoffmann-Thiel, S., Ingen, J. van, Jackson, S., Jaton, K., Lange, C., Stalder, J. M., O’Donnell, J., Opota, O., Peto, T. E. A., Preiswerk, B., Roycroft, E., Sato, M., Schacher, R., Schulthess, B., Smith, E. G., Soini, H., Sougakoff, W., Tagliani, E., Utpatel, C., Veziris, N., Wagner-Wiening, C. and Witschi, M. (2018). A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study. The Lancet Infectious Diseases 18, 431–440, http://doi.org/10.1016/S1473-3099(18)30004-5.
World Health Organization (2018). Technical Report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis, WHO, Geneva, URL: https://apps.who.int/iris/rest/bitstreams/1098393/retrieve.